CK improves near vision in post-LASIK and plano presbyopic eyes

NearVision conductive keratoplasty (CK) (Refractec) offers a minimally invasive method of enhancing near vision in plano presbyopes and in post-LASIK eyes, according to the results of an FDA presbyopia study and a CK post-LASIK study, as presented by Marguerite McDonald of Tulane University School of Medicine, New Orleans, USA.

During the FDA CK presbyopia study, 188 eyes of 150 patients were treated. At 24 months, there was good preservation of best spectacle corrected visual acuity (BCVA) with no eyes losing two or more lines of vision. No complications or adverse events were recorded. Fifty-three percent of eyes were within 0.50 D of intended correction and 91% were within 1 D. Uncorrected visual acuity (UCVA) results showed that 75% of eyes were J3 or better at 24 months and 51% were J2 or better.

In the post%LASIK study, 150 eyes of 150 patients were treated with CK at least one year after LASIK. By three months follow-up, no patients has lost two or more lines of vision or had a best spectacle corrected visual acuity (BSCVA) of 20/40 or worse. Ninety-six percent of patients achieved an uncorrected near vision of J3 or better, with 75% reading at J1 or better.

These results demonstrate that CK is an effective method of enhancing near vision in plano presbyopes and post-LASIK eyes.